-$1.38 Earnings Per Share Expected for Adamas Pharmaceuticals (ADMS) This Quarter

Equities research analysts expect Adamas Pharmaceuticals (NASDAQ:ADMS) to announce earnings per share (EPS) of ($1.38) for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Adamas Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.51) and the highest is ($1.17). Adamas Pharmaceuticals reported earnings of ($0.72) per share during the same quarter last year, which indicates a negative year over year growth rate of 91.7%. The business is scheduled to issue its next earnings report on Tuesday, May 8th.

According to Zacks, analysts expect that Adamas Pharmaceuticals will report full-year earnings of ($5.86) per share for the current fiscal year, with EPS estimates ranging from ($6.57) to ($5.25). For the next year, analysts expect that the company will post earnings of ($3.87) per share, with EPS estimates ranging from ($4.58) to ($2.68). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Adamas Pharmaceuticals.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported ($1.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.18) by ($0.09). The firm had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $0.84 million. During the same period in the prior year, the company earned ($0.68) earnings per share. The firm’s revenue for the quarter was up 1435.1% on a year-over-year basis.

A number of analysts recently commented on ADMS shares. BidaskClub upgraded shares of Adamas Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, January 25th. Needham & Company LLC set a $40.00 price target on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, February 25th. ValuEngine upgraded shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research upgraded shares of Adamas Pharmaceuticals from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a research note on Wednesday, January 3rd. Finally, William Blair restated an “outperform” rating on shares of Adamas Pharmaceuticals in a research note on Wednesday, February 21st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $42.67.

In other Adamas Pharmaceuticals news, insider Rajiv Patni sold 1,252 shares of the stock in a transaction that occurred on Wednesday, March 21st. The shares were sold at an average price of $25.94, for a total value of $32,476.88. Following the sale, the insider now directly owns 21,515 shares in the company, valued at approximately $558,099.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Gregory T. Went sold 4,541 shares of the stock in a transaction that occurred on Wednesday, March 21st. The stock was sold at an average price of $25.75, for a total transaction of $116,930.75. Following the completion of the sale, the chief executive officer now owns 182,610 shares in the company, valued at $4,702,207.50. The disclosure for this sale can be found here. Insiders have sold a total of 6,360 shares of company stock worth $164,138 over the last 90 days. 29.00% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of ADMS. SG Americas Securities LLC purchased a new stake in Adamas Pharmaceuticals in the 3rd quarter worth approximately $110,000. JPMorgan Chase & Co. lifted its stake in Adamas Pharmaceuticals by 13,028.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 136,273 shares of the specialty pharmaceutical company’s stock worth $2,839,000 after purchasing an additional 135,235 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its stake in Adamas Pharmaceuticals by 11.7% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 30,690 shares of the specialty pharmaceutical company’s stock worth $1,041,000 after purchasing an additional 3,218 shares in the last quarter. Hartwell J M Limited Partnership lifted its stake in Adamas Pharmaceuticals by 65.0% in the 4th quarter. Hartwell J M Limited Partnership now owns 16,500 shares of the specialty pharmaceutical company’s stock worth $559,000 after purchasing an additional 6,500 shares in the last quarter. Finally, American Century Companies Inc. purchased a new stake in Adamas Pharmaceuticals in the 4th quarter worth approximately $2,110,000. Institutional investors and hedge funds own 75.71% of the company’s stock.

Shares of Adamas Pharmaceuticals stock traded up $0.07 on Tuesday, reaching $28.20. 937,520 shares of the company traded hands, compared to its average volume of 999,694. Adamas Pharmaceuticals has a 52 week low of $13.50 and a 52 week high of $44.00. The company has a market capitalization of $753.02, a P/E ratio of -7.10 and a beta of 1.58. The company has a quick ratio of 10.69, a current ratio of 10.79 and a debt-to-equity ratio of 1.55.

COPYRIGHT VIOLATION WARNING: This article was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/3385810/1-38-earnings-per-share-expected-for-adamas-pharmaceuticals-adms-this-quarter.html.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.

Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Markel Co.  Vice Chairman Steven A. Markel Sells 200 Shares
Markel Co. Vice Chairman Steven A. Markel Sells 200 Shares
Bottomline Technologies, Inc.  Director Peter Gibson Purchases 4,000 Shares
Bottomline Technologies, Inc. Director Peter Gibson Purchases 4,000 Shares
Old Dominion Freight Line  Director Leo H. Suggs Sells 800 Shares of Stock
Old Dominion Freight Line Director Leo H. Suggs Sells 800 Shares of Stock
Cara Therapeutics  SVP Frederique Ph.D. Menzaghi Sells 9,000 Shares
Cara Therapeutics SVP Frederique Ph.D. Menzaghi Sells 9,000 Shares
Analysts Set Nexeo Solutions  Price Target at $11.17
Analysts Set Nexeo Solutions Price Target at $11.17
Hologic, Inc.  Given Average Recommendation of “Hold” by Analysts
Hologic, Inc. Given Average Recommendation of “Hold” by Analysts


© 2006-2018 Ticker Report. Google+.